{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,3]],"date-time":"2025-09-03T09:53:34Z","timestamp":1756893214161},"reference-count":68,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,9]]},"abstract":"<jats:p>Cholesterol metabolism and transport has been a major focus in cardiovascular disease risk modification over the past several decades. Hydroxymethylglutaryl-CoA reductase inhibitors (statins) have been the most commonly used agents, with the greatest benefit in reducing both the primary and secondary risks of cardiovascular disease. However, heart disease remains the leading cause of death in both men and women in the United States. Further investigation and intervention are required to further reduce the risk for cardiovascular disease and cardiovascular-related deaths. This review will focus on high-density lipoprotein metabolism and transport, looking particularly at cholesteryl ester transfer protein (CETP) inhibitors. While studies of the other CETP inhibitors in its class have not shown a significant improvement in the prevention of primary or secondary cardiovascular risk, anacetrapib, the fourth and latest of the CETP inhibitors to be investigated, may be more promising.<\/jats:p>","DOI":"10.1097\/crd.0000000000000245","type":"journal-article","created":{"date-parts":[[2018,12,31]],"date-time":"2018-12-31T07:41:12Z","timestamp":1546242072000},"page":"242-248","source":"Crossref","is-referenced-by-count":5,"title":["Is Anacetrapib Better Than Its CETP Inhibitor Counterparts?"],"prefix":"10.1097","volume":"27","author":[{"given":"Mordechai","family":"Grabie","sequence":"first","affiliation":[{"name":"Departments of Medicine, Hofstra-Northwell School of Medicine, Manhasset, NY"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cheng-Hung","family":"Tai","sequence":"additional","affiliation":[{"name":"Northwell Health, Lenox Hill Hospital, New York, NY"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William H.","family":"Frishman","sequence":"additional","affiliation":[{"name":"Westchester Medical Center, New York Medical College, Valhalla, NY."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R2-20230903","first-page":"e29","article-title":"Heart disease and stroke statistics\u20132015 update: a report from the American Heart Association.","volume":"131","author":"Mozaffarian","year":"2015","journal-title":"Circulation"},{"key":"R3-20230903","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1161\/CIR.0b013e31820a55f5","article-title":"Forecasting the future of cardiovascular disease in the United States: a policy statement from the American Heart Association.","volume":"123","author":"Heidenreich","year":"2011","journal-title":"Circulation"},{"key":"R4-20230903","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1056\/NEJM199811053391902","article-title":"Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol level.","volume":"339","year":"1998","journal-title":"N Engl J Med"},{"key":"R5-20230903","doi-asserted-by":"crossref","first-page":"2823","DOI":"10.1001\/jama.1986.03380200061022","article-title":"Is relationship between serum cholesterol and risk of premature death from coronary heart disease continuous and graded? Findings in 356,222 primary screenees of the Multiple Risk Factor Intervention Trial (MRFIT).","volume":"256","author":"Stamler","year":"1986","journal-title":"JAMA"},{"key":"R6-20230903","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1136\/bmj.308.6925.363","article-title":"Systematic underestimation of association between serum cholesterol concentration and ischaemic heart disease in observational studies: data from the BUPA study.","volume":"308","author":"Law","year":"1994","journal-title":"BMJ"},{"key":"R7-20230903","first-page":"1383","article-title":"Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S).","volume":"344","year":"1994","journal-title":"Lancet"},{"key":"R8-20230903","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1056\/NEJM199610033351401","article-title":"The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators.","volume":"335","author":"Sacks","year":"1996","journal-title":"N Engl J Med"},{"key":"R9-20230903","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1056\/NEJMoa1001282","article-title":"Effects of combination lipid therapy in type 2 diabetes mellitus.","volume":"362","author":"Ginsberg","year":"2010","journal-title":"N Engl J Med"},{"key":"R10-20230903","doi-asserted-by":"crossref","first-page":"2255","DOI":"10.1056\/NEJMoa1107579","article-title":"Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy.","volume":"365","author":"Boden","year":"2011","journal-title":"N Engl J Med"},{"key":"R11-20230903","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.1001\/jamainternmed.2014.3404","article-title":"Trends in use of ezetimibe after the ENHANCE trial, 2007 through 2010.","volume":"174","author":"Ross","year":"2014","journal-title":"JAMA Intern Med"},{"key":"R12-20230903","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1016\/0002-9149(92)90550-I","article-title":"Relation of high-density lipoprotein cholesterol and triglycerides to incidence of atherosclerotic coronary artery disease (the PROCAM experience). Prospective Cardiovascular M\u00fcnster study.","volume":"70","author":"Assmann","year":"1992","journal-title":"Am J Cardiol"},{"key":"R13-20230903","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1016\/S0140-6736(77)92274-7","article-title":"The Troms\u00f8 heart-study. High-density lipoprotein and coronary heart-disease: a prospective case-control study.","volume":"1","author":"Miller","year":"1977","journal-title":"Lancet"},{"key":"R14-20230903","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1161\/01.CIR.79.1.8","article-title":"High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies.","volume":"79","author":"Gordon","year":"1989","journal-title":"Circulation"},{"key":"R15-20230903","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/0002-9343(77)90874-9","article-title":"High density lipoprotein as a protective factor against coronary heart disease. The Framingham Study.","volume":"62","author":"Gordon","year":"1977","journal-title":"Am J Med"},{"key":"R16-20230903","doi-asserted-by":"crossref","first-page":"4880","DOI":"10.1021\/jm200484c","article-title":"Biphenyl-substituted oxazolidinones as cholesteryl ester transfer protein inhibitors: modifications of the oxazolidinone ring leading to the discovery of anacetrapib.","volume":"54","author":"Smith","year":"2011","journal-title":"J Med Chem"},{"issue":"suppl","key":"R17-20230903","doi-asserted-by":"crossref","first-page":"S195","DOI":"10.1194\/jlr.R800034-JLR200","article-title":"The metabolism and anti-atherogenic properties of HDL.","volume":"50","author":"Rye","year":"2009","journal-title":"J Lipid Res"},{"key":"R18-20230903","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1146\/annurev.bi.64.070195.001315","article-title":"Plasma lipid transfer proteins.","volume":"64","author":"Tall","year":"1995","journal-title":"Annu Rev Biochem"},{"key":"R19-20230903","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1161\/CIRCULATIONAHA.111.066589","article-title":"Cholesterol efflux and atheroprotection: advancing the concept of reverse cholesterol transport.","volume":"125","author":"Rosenson","year":"2012","journal-title":"Circulation"},{"key":"R20-20230903","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/j.cmet.2008.03.001","article-title":"HDL, ABC transporters, and cholesterol efflux: implications for the treatment of atherosclerosis.","volume":"7","author":"Tall","year":"2008","journal-title":"Cell Metab"},{"key":"R21-20230903","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1172\/JCI115532","article-title":"Monocyte transmigration induced by modification of low density lipoprotein in cocultures of human aortic wall cells is due to induction of monocyte chemotactic protein 1 synthesis and is abolished by high density lipoprotein.","volume":"88","author":"Navab","year":"1991","journal-title":"J Clin Invest"},{"key":"R22-20230903","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1161\/01.RES.0000225982.01988.93","article-title":"Endothelial and antithrombotic actions of HDL.","volume":"98","author":"Mineo","year":"2006","journal-title":"Circ Res"},{"key":"R23-20230903","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1161\/01.ATV.0000216600.37436.cf","article-title":"High-density lipoproteins enhance progenitor-mediated endothelium repair in mice.","volume":"26","author":"Tso","year":"2006","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"R24-20230903","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1161\/01.RES.0000199272.59432.5b","article-title":"High-density lipoprotein promotes endothelial cell migration and reendothelialization via scavenger receptor-B type I.","volume":"98","author":"Seetharam","year":"2006","journal-title":"Circ Res"},{"key":"R25-20230903","doi-asserted-by":"crossref","first-page":"2944","DOI":"10.1161\/01.CIR.0000070934.69310.1A","article-title":"Restoration of endothelial function by increasing high-density lipoprotein in subjects with isolated low high-density lipoprotein.","volume":"107","author":"Bisoendial","year":"2003","journal-title":"Circulation"},{"key":"R26-20230903","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1021\/cr020466v","article-title":"HDL: the metabolism, function, and therapeutic importance.","volume":"104","author":"Wang","year":"2004","journal-title":"Chem Rev"},{"key":"R27-20230903","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1038\/clpt.2011.271","article-title":"Anacetrapib, a novel CETP inhibitor: pursuing a new approach to cardiovascular risk reduction.","volume":"91","author":"Gutstein","year":"2012","journal-title":"Clin Pharmacol Ther"},{"key":"R28-20230903","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1038\/342448a0","article-title":"Molecular basis of lipid transfer protein deficiency in a family with increased high-density lipoproteins.","volume":"342","author":"Brown","year":"1989","journal-title":"Nature"},{"key":"R29-20230903","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/S0021-9150(02)00327-1","article-title":"Prevalence and phenotypic spectrum of cholesteryl ester transfer protein gene mutations in Japanese hyperalphalipoproteinemia.","volume":"166","author":"Maruyama","year":"2003","journal-title":"Atherosclerosis"},{"key":"R30-20230903","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1194\/jlr.M200024-JLR200","article-title":"Two novel missense mutations in the CETP gene in Japanese hyperalphalipoproteinemic subjects: high-throughput assay by Invader assay.","volume":"43","author":"Nagano","year":"2002","journal-title":"J Lipid Res"},{"key":"R31-20230903","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1038\/364073a0","article-title":"Severe atherosclerosis in transgenic mice expressing simian cholesteryl ester transfer protein.","volume":"364","author":"Marotti","year":"1993","journal-title":"Nature"},{"key":"R32-20230903","doi-asserted-by":"crossref","first-page":"27406","DOI":"10.1016\/S0021-9258(19)74263-X","article-title":"Down-regulation of mRNA for the low density lipoprotein receptor in transgenic mice containing the gene for human cholesteryl ester transfer protein. Mechanism to explain accumulation of lipoprotein B particles.","volume":"268","author":"Jiang","year":"1993","journal-title":"J Biol Chem"},{"key":"R33-20230903","doi-asserted-by":"crossref","first-page":"5033","DOI":"10.1074\/jbc.273.9.5033","article-title":"Effect of antisense oligonucleotides against cholesteryl ester transfer protein on the development of atherosclerosis in cholesterol-fed rabbits.","volume":"273","author":"Sugano","year":"1998","journal-title":"J Biol Chem"},{"key":"R34-20230903","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/S0022-2275(20)32082-4","article-title":"Low density lipoproteins develop resistance to oxidative modification due to inhibition of cholesteryl ester transfer protein by a monoclonal antibody.","volume":"41","author":"Sugano","year":"2000","journal-title":"J Lipid Res"},{"key":"R35-20230903","doi-asserted-by":"crossref","first-page":"1418","DOI":"10.1161\/01.CIR.0000141730.65972.95","article-title":"Plasma levels of cholesteryl ester transfer protein and the risk of future coronary artery disease in apparently healthy men and women: the prospective EPIC (European Prospective Investigation into Cancer and nutrition)-Norfolk population study.","volume":"110","author":"Boekholdt","year":"2004","journal-title":"Circulation"},{"key":"R36-20230903","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1111\/j.1365-2362.2004.01281.x","article-title":"Cholesteryl ester transfer protein concentration is associated with progression of atherosclerosis and response to pravastatin in men with coronary artery disease (REGRESS).","volume":"34","author":"Klerkx","year":"2004","journal-title":"Eur J Clin Invest"},{"key":"R37-20230903","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1161\/01.CIR.0000015857.31889.7B","article-title":"Efficacy and safety of a novel cholesteryl ester transfer protein inhibitor, JTT-705, in humans: a randomized phase II dose-response study.","volume":"105","author":"Grooth","year":"2002","journal-title":"Circulation"},{"key":"R38-20230903","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1016\/j.amjcard.2004.12.064","article-title":"Effectiveness of inhibition of cholesteryl ester transfer protein by JTT-705 in combination with pravastatin in type II dyslipidemia.","volume":"95","author":"Kuivenhoven","year":"2005","journal-title":"Am J Cardiol"},{"key":"R39-20230903","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1161\/01.ATV.0000118278.21719.17","article-title":"Raising high-density lipoprotein in humans through inhibition of cholesteryl ester transfer protein: an initial multidose study of torcetrapib.","volume":"24","author":"Clark","year":"2004","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"R40-20230903","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1056\/NEJMoa031766","article-title":"Effects of an inhibitor of cholesteryl ester transfer protein on HDL cholesterol.","volume":"350","author":"Brousseau","year":"2004","journal-title":"N Engl J Med"},{"issue":"suppl II","key":"R41-20230903","first-page":"179","article-title":"Effects of torcetrapib and\/or atorvastatin on HDL and LDL particle size and composition: results from a Phase 2 trial.","volume":"112","author":"Thuren","year":"2005","journal-title":"Circulation"},{"key":"R42-20230903","doi-asserted-by":"crossref","first-page":"2109","DOI":"10.1056\/NEJMoa0706628","article-title":"Effects of torcetrapib in patients at high risk for coronary events.","volume":"357","author":"Barter","year":"2007","journal-title":"N Engl J Med"},{"key":"R43-20230903","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1056\/NEJMoa070635","article-title":"Effect of torcetrapib on the progression of coronary atherosclerosis.","volume":"356","author":"Nissen","year":"2007","journal-title":"N Engl J Med"},{"key":"R44-20230903","doi-asserted-by":"crossref","first-page":"1620","DOI":"10.1056\/NEJMoa071359","article-title":"Effect of torcetrapib on carotid atherosclerosis in familial hypercholesterolemia.","volume":"356","author":"Kastelein","year":"2007","journal-title":"N Engl J Med"},{"key":"R45-20230903","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/S0140-6736(07)61088-5","article-title":"Torcetrapib and carotid intima-media thickness in mixed dyslipidaemia (RADIANCE 2 study): a randomised, double-blind trial.","volume":"370","author":"Bots","year":"2007","journal-title":"Lancet"},{"key":"R46-20230903","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1097\/FJC.0b013e3181cf03cb","article-title":"Torcetrapib produces endothelial dysfunction independent of cholesteryl ester transfer protein inhibition.","volume":"55","author":"Connelly","year":"2010","journal-title":"J Cardiovasc Pharmacol"},{"key":"R47-20230903","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1001\/jama.2009.1619","article-title":"Emerging Risk Factors Collaboration. Major lipids, apolipoproteins, and risk of vascular disease.","volume":"302","author":"Di Angelantonio","year":"2009","journal-title":"JAMA"},{"key":"R48-20230903","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1038\/bjp.2008.229","article-title":"Torcetrapib-induced blood pressure elevation is independent of CETP inhibition and is accompanied by increased circulating levels of aldosterone.","volume":"154","author":"Forrest","year":"2008","journal-title":"Br J Pharmacol"},{"key":"R49-20230903","doi-asserted-by":"crossref","first-page":"2211","DOI":"10.1210\/en.2008-1512","article-title":"Torcetrapib induces aldosterone and cortisol production by an intracellular calcium-mediated mechanism independently of cholesteryl ester transfer protein inhibition.","volume":"150","author":"Hu","year":"2009","journal-title":"Endocrinology"},{"key":"R50-20230903","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1097\/FJC.0b013e3181cf03cb","article-title":"Torcetrapib produces endothelial dysfunction independent of cholesteryl ester transfer protein inhibition.","volume":"55","author":"Connelly","year":"2010","journal-title":"J Cardiovasc Pharmacol"},{"key":"R51-20230903","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1097\/HJH.0b013e32833b1f8e","article-title":"Mechanisms underlying off-target effects of the cholesteryl ester transfer protein inhibitor torcetrapib involve L-type calcium channels.","volume":"28","author":"Clerc","year":"2010","journal-title":"J Hypertens"},{"key":"R52-20230903","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1093\/eurheartj\/ehs019","article-title":"Vascular effects and safety of dalcetrapib in patients with or at risk of coronary heart disease: the dal-VESSEL randomized clinical trial.","volume":"33","author":"L\u00fcscher","year":"2012","journal-title":"Eur Heart J"},{"key":"R53-20230903","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.amjcard.2009.02.061","article-title":"Safety and tolerability of dalcetrapib.","volume":"104","author":"Stein","year":"2009","journal-title":"Am J Cardiol"},{"key":"R54-20230903","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1016\/S0140-6736(11)61383-4","article-title":"Safety and efficacy of dalcetrapib on atherosclerotic disease using novel non-invasive multimodality imaging (dal-PLAQUE): a randomised clinical trial.","volume":"378","author":"Fayad","year":"2011","journal-title":"Lancet"},{"key":"R55-20230903","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.1056\/NEJMoa1206797","article-title":"Effects of dalcetrapib in patients with a recent acute coronary syndrome.","volume":"367","author":"Schwartz","year":"2012","journal-title":"N Engl J Med"},{"key":"R56-20230903","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1111\/jphp.12287","article-title":"Effects of the cholesteryl ester transfer protein inhibitor evacetrapib on lipoproteins, apolipoproteins and 24-h ambulatory blood pressure in healthy adults.","volume":"66","author":"Suico","year":"2014","journal-title":"J Pharm Pharmacol"},{"key":"R58-20230903","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1177\/1074248413510784","article-title":"Evacetrapib at a supratherapeutic steady state concentration does not prolong QT in a thorough QT\/QTc study in healthy participants.","volume":"19","author":"Suico","year":"2014","journal-title":"J Cardiovasc Pharmacol Ther"},{"key":"R59-20230903","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.1001\/jama.2011.1649","article-title":"Effects of the CETP inhibitor evacetrapib administered as monotherapy or in combination with statins on HDL and LDL cholesterol: a randomized controlled trial.","volume":"306","author":"Nicholls","year":"2011","journal-title":"JAMA"},{"key":"R60-20230903","doi-asserted-by":"crossref","first-page":"2021","DOI":"10.1016\/j.amjcard.2014.03.045","article-title":"Efficacy, safety, tolerability, and pharmacokinetic profile of evacetrapib administered as monotherapy or in combination with atorvastatin in Japanese patients with dyslipidemia.","volume":"113","author":"Teramoto","year":"2014","journal-title":"Am J Cardiol"},{"key":"R63-20230903","doi-asserted-by":"crossref","first-page":"1907","DOI":"10.1016\/S0140-6736(07)61813-3","article-title":"Effect of the cholesteryl ester transfer protein inhibitor, anacetrapib, on lipoproteins in patients with dyslipidaemia and on 24-h ambulatory blood pressure in healthy individuals: two double-blind, randomised placebo-controlled phase I studies.","volume":"370","author":"Krishna","year":"2007","journal-title":"Lancet"},{"key":"R64-20230903","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1016\/j.ahj.2008.09.022","article-title":"Efficacy and safety of the cholesteryl ester transfer protein inhibitor anacetrapib as monotherapy and coadministered with atorvastatin in dyslipidemic patients.","volume":"157","author":"Bloomfield","year":"2009","journal-title":"Am Heart J"},{"key":"R65-20230903","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1016\/j.ahj.2011.07.010","article-title":"Efficacy and safety after cessation of treatment with the cholesteryl ester transfer protein inhibitor anacetrapib (MK-0859) in patients with primary hypercholesterolemia or mixed hyperlipidemia.","volume":"162","author":"Dansky","year":"2011","journal-title":"Am Heart J"},{"key":"R66-20230903","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1038\/clpt.2008.109","article-title":"Multiple-dose pharmacodynamics and pharmacokinetics of anacetrapib, a potent cholesteryl ester transfer protein (CETP) inhibitor, in healthy subjects.","volume":"84","author":"Krishna","year":"2008","journal-title":"Clin Pharmacol Ther"},{"key":"R67-20230903","doi-asserted-by":"crossref","first-page":"2406","DOI":"10.1056\/NEJMoa1009744","article-title":"Safety of anacetrapib in patients with or at high risk for coronary heart disease.","volume":"363","author":"Cannon","year":"2010","journal-title":"N Engl J Med"},{"key":"R68-20230903","doi-asserted-by":"crossref","first-page":"2153","DOI":"10.1016\/S0140-6736(14)62115-2","article-title":"Anacetrapib as lipid-modifying therapy in patients with heterozygous familial hypercholesterolaemia (REALIZE): a randomised, double-blind, placebo-controlled, phase 3 study.","volume":"385","author":"Kastelein","year":"2015","journal-title":"Lancet"},{"key":"R69-20230903","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1056\/NEJMoa1706444","article-title":"Effects of anacetrapib in patients with atherosclerotic vascular disease.","volume":"377","year":"2017","journal-title":"N Engl J Med"},{"key":"R70-20230903","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1161\/CIRCRESAHA.117.311978","article-title":"Trials and tribulations of CETP inhibitors.","volume":"122","author":"Tall","year":"2018","journal-title":"Circ Res"},{"key":"R71-20230903","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/j.jacc.2018.10.072","article-title":"Cholesteryl ester transfer protein inhibition for preventing cardiovascular events.","volume":"73","author":"Armitage","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"R72-20230903","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1161\/CIRCGENETICS.116.001405","article-title":"Genotype-dependent effects of dalcetrapib on cholesterol efflux and inflammation: concordance with clinical outcomes.","volume":"9","author":"Tardif","year":"2016","journal-title":"Circ Cardiovasc Genet"}],"container-title":["Cardiology in Review"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/CRD.0000000000000245","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,3]],"date-time":"2023-09-03T09:12:58Z","timestamp":1693732378000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/CRD.0000000000000245"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9]]},"references-count":68,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2019]]}},"URL":"https:\/\/doi.org\/10.1097\/crd.0000000000000245","relation":{},"ISSN":["1061-5377"],"issn-type":[{"value":"1061-5377","type":"print"}],"subject":[],"published":{"date-parts":[[2019,9]]}}}